Precision Biosciences Inc (NASDAQ: DTIL)’s stock price has decreased by -9.47 compared to its previous closing price of 7.18. However, the company has seen a -15.58% decrease in its stock price over the last five trading sessions. businesswire.com reported 2024-11-21 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. JonesTrading Virtual Genetic Medicine Day Date: Monday, November 25, 2024 Time: 11:00 AM ET Panel Title: Next Generation of Gene Editing; Going Beyond “Cas” Webcast Link: Regist.
Is It Worth Investing in Precision Biosciences Inc (NASDAQ: DTIL) Right Now?
Precision Biosciences Inc (NASDAQ: DTIL) has a price-to-earnings ratio of 127.20x that is above its average ratio. Additionally, the 36-month beta value for DTIL is 1.43. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DTIL is 3.72M and currently, short sellers hold a 5.77% ratio of that float. The average trading volume of DTIL on November 22, 2024 was 71.02K shares.
DTIL’s Market Performance
DTIL stock saw a decrease of -15.58% in the past week, with a monthly decline of -23.98% and a quarterly a decrease of -32.92%. The volatility ratio for the week is 6.41%, and the volatility levels for the last 30 days are 5.31% for Precision Biosciences Inc (DTIL). The simple moving average for the last 20 days is -19.08% for DTIL stock, with a simple moving average of -38.80% for the last 200 days.
Analysts’ Opinion of DTIL
Many brokerage firms have already submitted their reports for DTIL stocks, with Guggenheim repeating the rating for DTIL by listing it as a “Buy.” The predicted price for DTIL in the upcoming period, according to Guggenheim is $19 based on the research report published on April 30, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see DTIL reach a price target of $7. The rating they have provided for DTIL stocks is “Outperform” according to the report published on June 17th, 2022.
DTIL Trading at -25.58% from the 50-Day Moving Average
After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.55% of loss for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 6.41%, as shares sank -23.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.04% lower at present.
During the last 5 trading sessions, DTIL fell by -15.58%, which changed the moving average for the period of 200-days by -45.83% in comparison to the 20-day moving average, which settled at $8.03. In addition, Precision Biosciences Inc saw -40.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DTIL starting from Kelly John Alexander, who purchase 3,000 shares at the price of $6.76 back on Nov 21 ’24. After this action, Kelly John Alexander now owns 38,073 shares of Precision Biosciences Inc, valued at $20,280 using the latest closing price.
Scimeca Dario, the General Counsel and Secretary of Precision Biosciences Inc, sale 588 shares at $8.19 during a trade that took place back on Nov 04 ’24, which means that Scimeca Dario is holding 7,969 shares at $4,816 based on the most recent closing price.
Stock Fundamentals for DTIL
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.93 for the gross margin
The net margin for Precision Biosciences Inc stands at 0.11. The total capital return value is set at -0.08. Equity return is now at value 24.44, with 7.23 for asset returns.
Based on Precision Biosciences Inc (DTIL), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.05. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -5.77.
Currently, EBITDA for the company is -32.04 million with net debt to EBITDA at -3.64. When we switch over and look at the enterprise to sales, we see a ratio of -0.25. The receivables turnover for the company is 48.54for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.22.
Conclusion
In conclusion, Precision Biosciences Inc (DTIL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
